Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid and advanced skin cancer. This FDA recap highlights recent approvals in April ...

A groundbreaking NHS therapy for myeloma uses a 'Trojan horse' approach to target cancer cells, offering longer remission, ...

A new study details the development of a nanoparticle-based system that delivers concentrated chemotherapy specifically to ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A daily medication relied on by more than half a million women is under urgent recall after a critical test failure raised fears it may not be doing its job.

Pfizer PFE has committed significant resources for the development of treatments in the fields of oncology, internal medicine ...

UC San Diego scientists are testing a new potential cancer treatment in space. Why it matters: The NASA-funded mission will ...

Despite recent ASCO and FDA guidance recommending the inclusion of people living with HIV in pivotal cancer trials, nearly 75 ...

Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to ...

UnitedHealthcare and Memorial Sloan Kettering have been locked in a contract dispute that wasn’t resolved by the overnight ...

BerGenBio, reeling from the failure of its lead cancer drug, has opted to merge with fellow Norwegian cancer biotech Oncoinvent.

Sigvotatug Vedotin is an ADC that targets integrin αvβ6-positive tumor cells. It has an engineered antibody that ensures high ...